The application of the Russian single-dose Sputnik Light vaccine has demonstrated 70% efficacy against the Delta variant of the coronavirus in the three months after vaccination, according to a statement issued this Wednesday from the Russian Direct Investment Fund (RDIF) and the National Research Center for Epidemiology and Microbiology.
In people under the age of 60, the efficacy of Sputnik Light exceeded the 75 %. On the other hand, it is emphasized that the efficacy of the vaccine against severe cases and hospitalization is even higher.
The results were obtained after analyzing the data from 28,000 people vaccinated with Sputnik Light in Moscow (Russia) compared to the control group of 5.6 million unvaccinated people based on data for July 2021.
“Indicators of the effectiveness of Sputnik Light against the Delta variant exceed the indicators of foreign vaccines of two components that demonstrate a significant decrease in efficacy below 50%, five months after vaccination, “the statement reads. In comparison, the efficacy of Pfizer’s vaccine decreased from 88 to 47% 5 months after the administration of the second dose.
Data obtained during the course of vaccination campaigns in other countries also confirm the high safety and efficacy of the Sputnik Light vaccine. In Argentina, a study has shown efficacy against coronavirus infection among the 78,6 % and the 83,7 %, and between 82.1% and 87.6% compared to hospitalization for people between 60 and 79 years old. On the other hand, the results of the vaccination campaign in Paraguay have shown an efficacy of the 93,5 % of the Russian single-dose vaccine in that country.
Flexible and easy to apply
In addition, from the RDIF they pointed out that inoculation with this drug has a series of key advantages, including easy application and its flexible use as a booster dose. Thus, the efficacy of Sputnik Light against the Delta variant will be close to the levels reached by the Sputnik V vaccine, whose effectiveness exceeds the 83 % against infection and more than one 94 % against hospitalization.
“The Sputnik Light vaccine is a good solution for countries with low vaccination rates thanks to its one-component scheme, it can be used successfully to maintain the immunity of the existing population as a booster dose “, underlined the deputy director of the Gamaleya Center, Denís Logunov.
Universal booster vaccine
For his part, Kirill Dmitriev, general director of the RDIF, recalled that the single-dose vaccine has also shown high efficacy when used with other vaccines, a fact that could make it a universal booster vaccine.
On the other hand, the increase in cases of infection with the Delta strain in the US and Israel, last August, shows that mRNA vaccines they need a heterogeneous ‘booster’ to reinforce and prolong the immune response, something that has been achieved in Argentina, where the use of the Russian vaccine Sputnik V made it possible to considerably reduce the number of infections.
Likewise, a study carried out in the province of Buenos Aires showed that the first dose of Sputnik V, in combination with the AstraZeneca, Sinopharm and Moderna vaccines, has good immunity and safety results. Meanwhile, preliminary data, generated from the observation of the first 20 participants in Azerbaijan, who received the vaccine in combination with the AstraZeneca drug, have shown that the 100% of the volunteers developed antibodies against the coronavirus.
The article addressing the study results was submitted to the MedRxiv prepress server for publication this week.
- The Sputnik Light vaccine consists of one of the components of Sputnik V – recombinant adenoviral vectors based on serotype 26 (component I, rAd26) – and has been registered in more than 15 countries, while it is currently found in 30 more countries. pending for registration.
Disclaimer: This article is generated from the feed and not edited by our team.
